BCL2 and diffuse large B-cell lymphoma: In contrast, some studies have shown that the addition of drugs to the treatment regimens of different subgroups of DLBCL patients could increase their efficacy or survival benefits [25, 26]; for example, the venetoclax plus R-CHOP regimen improved the outcomes of patients with Bcl-2-positive DLBCL [27].